Orlistat MRI Study

• Research type

  Research Study

• Full title

  A Longitudinal MRI study of changes in regional body composition during Orlistat (60mg)- assisted dieting.

• IRAS ID

  7784

• Contact name

  John Beaver

• Sponsor organisation

  GlaxoSmithKline

• Eudract number

  2008-004866-15

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  There are a number of different types of body fat. However, most measures used in obesity research (e.g., total body fat, body weight, waist circumference, body mass index) provide limited or no information on specific types of fat. The main aim of this study is to use MRI-based measures of specific fat types to assess whether weight loss treatment combining a reduced calorie, low fat diet with orlistat 60mg is accompanied by a reduction in visceral fat (the fat in and among the internal organs). We have previously shown that this treatment combination is more effective than diet plus placebo in helping patients reduce their weight. However we do not know whether this weight loss is associated with reductions in visceral fat, or some other tissue oflud in the body. Assessing visceral fat is important because it is believed to be more relevant to a range of health risks and clinical conditions than most other body fats.

• REC name

  London - Camberwell St Giles Research Ethics Committee

• REC reference

  08/H0807/88

• Date of REC Opinion

  18 Dec 2008

• REC opinion

  Further Information Favourable Opinion